100 related articles for article (PubMed ID: 30407727)
1. ETP-ALL with aberrant B marker expression: Case series and a brief review of literature.
Garg S; Gupta SK; Bakhshi S; Mallick S; Kumar L
Int J Lab Hematol; 2019 Apr; 41(2):e32-e37. PubMed ID: 30407727
[No Abstract] [Full Text] [Related]
2. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
Angelova E; Audette C; Kovtun Y; Daver N; Wang SA; Pierce S; Konoplev SN; Khogeer H; Jorgensen JL; Konopleva M; Zweidler-McKay PA; Medeiros LJ; Kantarjian HM; Jabbour EJ; Khoury JD
Haematologica; 2019 Apr; 104(4):749-755. PubMed ID: 30361418
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia.
Coskun E; Neumann M; Schlee C; Liebertz F; Heesch S; Goekbuget N; Hoelzer D; Baldus CD
Leuk Res; 2013 Jun; 37(6):647-56. PubMed ID: 23522449
[TBL] [Abstract][Full Text] [Related]
4. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia.
Akahane K; Murakami Y; Kagami K; Abe M; Harama D; Shinohara T; Watanabe A; Goi K; Nishi R; Yamauchi T; Kimura S; Takita J; Look AT; Minegishi M; Sugita K; Inukai T
Hematol Oncol; 2019 Oct; 37(4):516-519. PubMed ID: 31335977
[No Abstract] [Full Text] [Related]
5. Low LEF1 expression is a biomarker of early T-cell precursor, an aggressive subtype of T-cell lymphoblastic leukemia.
Wang M; Zhang C
PLoS One; 2020; 15(5):e0232520. PubMed ID: 32401815
[TBL] [Abstract][Full Text] [Related]
6. Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL.
Anand P; Guillaumet-Adkins A; Dimitrova V; Yun H; Drier Y; Sotudeh N; Rogers A; Ouseph MM; Nair M; Potdar S; Isenhart R; Kloeber JA; Vijaykumar T; Niu L; Vincent T; Guo G; Frede J; Harris MH; Place AE; Silverman LB; Teachey DT; Lane AA; DeAngelo DJ; Aster JC; Bernstein BE; Lohr JG; Knoechel B
Blood; 2021 May; 137(18):2463-2480. PubMed ID: 33227818
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL.
Chopra A; Bakhshi S; Pramanik SK; Pandey RM; Singh S; Gajendra S; Gogia A; Chandramohan J; Sharma A; Kumar L; Seth R; Rai S; Kumar R
Eur J Haematol; 2014 Mar; 92(3):211-8. PubMed ID: 24329989
[TBL] [Abstract][Full Text] [Related]
8. T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation.
Dorfman DM; Morgan EA; Pelton A; Unitt C
Hum Pathol; 2017 Jul; 65():166-174. PubMed ID: 28551327
[TBL] [Abstract][Full Text] [Related]
9. Differential WNT gene expression in various subtypes of acute lymphoblastic leukemia.
Memarian A; Vosough P; Asgarian-Omran H; Tabrizi M; Shabani M; Shokri F
Iran J Immunol; 2012 Mar; 9(1):61-71. PubMed ID: 22426169
[TBL] [Abstract][Full Text] [Related]
10. [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
Pan Y; Li GD; Liu WP; Zhang WY; Tang Y; Li FY
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):810-5. PubMed ID: 20193455
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy.
Du W; Li J; Liu W; He Y; Yao J; Liu Y; Lin J; Zheng J
Tumour Biol; 2016 Mar; 37(3):3817-21. PubMed ID: 26474588
[TBL] [Abstract][Full Text] [Related]
12. MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.
Colomer-Lahiguera S; Pisecker M; König M; Nebral K; Pickl WF; Kauer MO; Haas OA; Ullmann R; Attarbaschi A; Dworzak MN; Strehl S
Leuk Lymphoma; 2017 Dec; 58(12):2895-2904. PubMed ID: 28482719
[TBL] [Abstract][Full Text] [Related]
13. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
[TBL] [Abstract][Full Text] [Related]
14. Malignancy-Associated Hypercalcemia Related with Receptor Activator of NF-κB Ligand (RANKL) Expression in T-Cell Acute Lymphoblastic Leukemia.
Tahara K; Koiso H; Osaki YH; Sekigami T; Yokohama A; Saitoh T; Tsukamoto N; Murakami H; Abe M; Handa H
Acta Haematol; 2019; 141(3):135-137. PubMed ID: 30783036
[No Abstract] [Full Text] [Related]
15. CD123 Immunohistochemical Expression Is a Specific But Insensitive Marker of Early T-precursor Leukemia.
Hellman C; Marcogliese AN; Djokic M; Roth CG
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):e4-5. PubMed ID: 25906118
[No Abstract] [Full Text] [Related]
16. Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia.
Xi Y; Li J; Zan L; Wang J; Wang G; Ning Y
Hum Pathol; 2013 Jun; 44(6):1011-6. PubMed ID: 23260326
[TBL] [Abstract][Full Text] [Related]
17. Early T-cell precursor leukemia/lymphoma in adults and children.
Allen A; Sireci A; Colovai A; Pinkney K; Sulis M; Bhagat G; Alobeid B
Leuk Res; 2013 Sep; 37(9):1027-34. PubMed ID: 23827350
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker.
Nasr MR; Rosenthal N; Syrbu S
Am J Clin Pathol; 2010 Jan; 133(1):41-8. PubMed ID: 20023257
[TBL] [Abstract][Full Text] [Related]
19. Influence of aberrant myeloid expression on acute lymphoblastic leukemia in children and adolescents from Maranhão, Brazil.
Lopes TC; Andrade KN; Camelo NL; Rodrigues VP; Oliveira RA
Genet Mol Res; 2014 Dec; 13(4):10301-7. PubMed ID: 25501242
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
